Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) announced its earnings results on Friday. The specialty pharmaceutical company reported ($0.83) EPS for the quarter, Zacks reports.
Titan Pharmaceuticals Trading Up 1.3 %
TTNP stock opened at $3.23 on Friday. The business’s 50 day moving average price is $3.72 and its two-hundred day moving average price is $4.97. Titan Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $14.80.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on shares of Titan Pharmaceuticals in a research report on Saturday. They issued a “sell” rating for the company.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- What is a Secondary Public Offering? What Investors Need to Know
- Nebius Group: The Rising Star in AI Infrastructure
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- MarketBeat Week in Review – 12/30 – 1/03
- What Are Dividend Champions? How to Invest in the Champions
- Is The Dip in Tesla a Buying Opportunity Ahead of FSD Potential?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
